Christopher J. Hawkey

Author

University of Nottingham

Also Known As

C HAWKEY, C Hawkey, C J HAWKEY, C J Hawkey, C. Hawkey, C. J. HAWKEY, C. J. Hawkey, C.J Hawkey, C.J. HAWKEY, C.J. Hawkey

243

Publications

20.7K

Citations

H-Index

118

Concepts

All Affiliations

University of Nottingham Queen's Medical Centre NIHR Nottingham Digestive Diseases Biomedical Research Unit Nottingham City Hospital Novartis (Switzerland)

About

Christopher J. Hawkey is an author at University of Nottingham specializing in medicine, gastroenterology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	50	5.3K
2	Health Sciences	6	6	486
3	Public Health	3	3	357
4	Natural Sciences	2	2	369
5	Engineering	1	1	126

Christopher J. Hawkey

101

Publications

15.7K

Citations

H-Index

Page 1

	Year	Citations
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis Claire Bombardier, Loren Laine, Alise Reicin, New England Journal of Medicine	2000	4K
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs Christopher J. Hawkey, Jeffrey A. Karrasch, L Szczepański, New England Journal of Medicine	1998	862
A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs Neville D. Yeomans, Zsolt Tulassay, L Juhász, New England Journal of Medicine	1998	765
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler, The Lancet RheumatologyAnti-inflammatoryAnti-inflammatory AgentsGastrointestinal PharmacologyMedicine	2004	700
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Michael E. Farkouh, Howard S. Kirshner, Robert A. Harrington, The Lancet Rheumatoid DisorderRheumatologyAnti-inflammatoryCardiovascular OutcomesGastrointestinal Event Trial	2004	490
Nitric oxide synthase activity in ulcerative colitis and Crohn's disease N. K. Boughton-Smith, Sue Evans, Brendan J.R. Whittle, The Lancet InflammationReactive Nitrogen SpecieImmunologyGastroenterologyPathology	1993	469
Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory Drugs Ali S. Taha, N Hudson, Christopher J. Hawkey, New England Journal of Medicine	1996	440
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial Ian Roberts, Haleema Shakur‐Still, Adefemi Afolabi, The Lancet	2020	369
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial Christopher J. Hawkey, Loren Laine, Thomas Simon, Arthritis & Rheumatism	2000	365
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use Loren Laine, L. Connors, Alise Reicin, Gastroenterology Anti-inflammatory AgentsFunctional Gastrointestinal DisorderGastrointestinal PharmacologyGastroenterologyNonselective Nsaid	2003	355

Page 1